- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Increasing Trial Success with Natural History of Disease Studies
***Live: Wednesday, Oct. 7, 2020 at 10am EDT*** Integrating natural history of disease studies into the early clinical development planning process can accelerate drug development, improve the odds of regulatory approval and reimbursement, and bring new life-changing treatments to patients. Join the upcoming webinar to discover more. *** On demand available after final airing until Oct. 7, 2021.***
Register free: https://event.on24.com/wcc/r/2697927/E0C4C0C586388622C9327CD0F7EA6D8B
Summary
Natural history of disease studies help clinical researchers understand disease progression in poorly characterized diseases. Increasingly, these studies are also facilitating clinical development in rare diseases. When these observational studies are integrated into the early clinical development planning process, you can:
- Accelerate drug development
- Meet regulatory requirements
- Bring new life-changing treatments to patients
In this webinar, discover how to:
- Identify the principles to define the right strategy for natural history studies
- Design studies in a way that the data can be used as a future external comparator to a single arm trial
- Provide the required real world evidence to support regulatory filings
Speakers: Cassie Holt, PhD, MPH, CPH, Associate Director, Product Strategy Lead, Medical Affairs, Real World Solutions, IQVIA
Emily W. Bratton, PhD, MSPH, Associate Director, Epidemiology Epidemiology & Outcomes, Research, Real World Solutions, IQVIA
Time and Date: Wednesday, Oct. 7, 2020 at 10am EDT
On demand available after final airing until Oct. 7, 2021
Sponsor: IQVIA
Register free: https://event.on24.com/wcc/r/2697927/E0C4C0C586388622C9327CD0F7EA6D8B
